Filter Results
:
(179)
Show Results For
-
All HBS Web
(1,072)
- Faculty Publications (179)
Show Results For
-
All HBS Web
(1,072)
- Faculty Publications (179)
←
Page 9 of
179
Results
- August 2005 (Revised December 2006)
- Case
Procter & Gamble: Electronic Data Capture and Clinical Trial Management
By: Robert S. Huckman and Mark J. Cotteleer
Considers whether the management of Procter & Gamble (P&G) Pharmaceuticals should adopt Web-based electronic data capture (EDC) as the default standard for the management of its clinical drug trials. Provides a detailed description of the existing paper-based process...
View Details
Keywords:
Health Testing and Trials;
Internet and the Web;
Information Technology;
Adoption;
Business Processes;
Industry Structures;
Technological Innovation;
Service Operations;
Pharmaceutical Industry;
United States
Huckman, Robert S., and Mark J. Cotteleer. "Procter & Gamble: Electronic Data Capture and Clinical Trial Management." Harvard Business School Case 606-033, August 2005. (Revised December 2006.)
- November 2003 (Revised September 2008)
- Case
Circle Gastroenterology Products (A)
By: Regina E. Herzlinger and James Weber
A new, minimally invasive medical device has achieved only one-third of its budget. Was the problem one of marketing strategy, sales, reimbursement, and/or clinical trials?
View Details
Keywords:
Health Testing and Trials;
Marketing Strategy;
Product Marketing;
Sales;
Medical Devices and Supplies Industry
Herzlinger, Regina E., and James Weber. "Circle Gastroenterology Products (A)." Harvard Business School Case 304-052, November 2003. (Revised September 2008.)
- August 2003 (Revised July 2023)
- Case
Fighting the Battle of the Bulge—Evaluating Do Good/Do Well Innovations in Morbid Obesity Treatment
By: Regina E. Herzlinger and John McDonough
What can Dr. Dean Ornish learn from the successes and failures of his competitors in ameliorating morbid obesity to create a business model that will “do good” by combatting obesity and associated chronic diseases and “do well” by growing a widely adopted business?...
View Details
Keywords:
Three Pillars;
Industry Analysis;
Health Disorders;
Health Care and Treatment;
Innovation and Invention;
Business Model;
Analysis;
Innovation and Management;
Medical Specialties;
Mission and Purpose;
Health Industry
Herzlinger, Regina E., and John McDonough. "Fighting the Battle of the Bulge—Evaluating Do Good/Do Well Innovations in Morbid Obesity Treatment." Harvard Business School Case 304-009, August 2003. (Revised July 2023.)
- April 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (A)
By: Sandra J. Sucher and Stacy McManus
Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the...
View Details
Keywords:
Decision Making;
Health Testing and Trials;
Innovation and Invention;
Markets;
Distribution;
Product Development;
Production;
Problems and Challenges;
Research;
Research and Development;
Complexity;
Biotechnology Industry;
Pharmaceutical Industry
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (A)." Harvard Business School Case 603-043, April 2003. (Revised October 2004.)
- December 2002
- Teaching Note
Abgenix and the XenoMouse (TN)
Teaching Note for (501-061).
View Details
- January 2001
- Case
Abgenix and the XenoMouse
By: Robert J. Dolan
Abgenix has a unique method for generating antibodies useful in treating a number of diseases, including cancer. In early 2000, the company's cancer has performed very well in animal testing and is moving to early stage human testing. Abgenix must decide whether to...
View Details
Keywords:
Product Development;
Marketing Strategy;
Health Testing and Trials;
Risk and Uncertainty;
Technological Innovation;
Innovation Strategy;
Science-Based Business;
Biotechnology Industry
Dolan, Robert J. "Abgenix and the XenoMouse." Harvard Business School Case 501-061, January 2001.
- May 1999 (Revised July 2000)
- Teaching Note
Reading Rehabilitation Hospital: Implementing Patient-Focused Care TN
By: Jody H. Gittell and Sandra J. Sucher
Teaching Note for (9-898-172). A rewritten version of an earlier teaching note.
View Details
- July 1998
- Supplement
Bell Atlantic in Union City
In this pioneering project to wire a school for the Internet and put computers in students' homes, Bell Atlantic combined its need for a beta site for a technology trial with the school reform efforts of the Union City, New Jersey public schools, under the leadership...
View Details
Keywords:
Business Model;
Social Enterprise;
Internet and the Web;
Education;
Business and Community Relations;
Education Industry;
New Jersey
Kanter, Rosabeth M. "Bell Atlantic in Union City." Harvard Business School Video Supplement 399-501, July 1998.
- 1996
- Chapter
The Determinants of Research Productivity in Ethical Drug Discovery
By: Rebecca M. Henderson and Ian Cockburn
- May 1993
- Case
Patient Transfusion Services Lab of Central Blood Bank
By: James L. Heskett
The vice president of the Lab and Clinical Services at Central Blood Bank is faced with the challenge of convincing a hospital to use economical shared patient transfusion testing services.
View Details
Keywords:
Health Care and Treatment;
Quality;
Service Operations;
Mathematical Methods;
Customer Satisfaction;
Health Industry
Heskett, James L. "Patient Transfusion Services Lab of Central Blood Bank." Harvard Business School Case 693-091, May 1993.
- April 1993 (Revised November 1994)
- Case
Chiron Corp.
Pablo Valenzuela, vice president of R&D at Chiron Corp., faces several choices for how to allocate scarce resources across several promising projects. These choices will determine Chiron's position in several emerging biotechnology and diagnostic markets, including...
View Details
Keywords:
Health Testing and Trials;
Research and Development;
Failure;
Business Strategy;
Joint Ventures;
Strategic Planning;
Opportunities;
Product Development;
Biotechnology Industry;
California
Wheelwright, Steven C. "Chiron Corp." Harvard Business School Case 693-052, April 1993. (Revised November 1994.)
- November 1991 (Revised April 1994)
- Case
Nucleon, Inc.
By: Gary P. Pisano
Nucleon is a small biotechnology company whose first potential product is about to enter clinical testing. Before Nucleon can begin clinical trials, however, its management must decide how and where to manufacture the product. Three options are being contemplated: 1)...
View Details
Keywords:
Factories, Labs, and Plants;
Entrepreneurship;
Health Testing and Trials;
Rights;
Product Development;
Production;
Partners and Partnerships;
Research and Development;
Biotechnology Industry
Pisano, Gary P. "Nucleon, Inc." Harvard Business School Case 692-041, November 1991. (Revised April 1994.)
- September 1991 (Revised August 1994)
- Background Note
Note on Pharmaceutical Industry Regulation
Traces the evolution of U.S. regulatory policy towards the pharmaceutical industry over the course of the twentieth century. A major theme is the steady shift away from a policy of 'let the buyer beware' to the creation of a complex and time-consuming review process,...
View Details
Keywords:
Safety;
Industry Growth;
Marketing;
Research and Development;
Health Testing and Trials;
Economics;
Pharmaceutical Industry;
United States
Emmons, Willis M., III. "Note on Pharmaceutical Industry Regulation." Harvard Business School Background Note 792-002, September 1991. (Revised August 1994.)
- 1984
- Book
The Results and Interpretation of Three Field Trials of Lysine Fortification of Cereals
By: James E. Austin, Jean Pierre Habicht, Max Milner, Vernon Young and Linda D. Myers
Austin, James E., Jean Pierre Habicht, Max Milner, Vernon Young, and Linda D. Myers. The Results and Interpretation of Three Field Trials of Lysine Fortification of Cereals. Washington, D.C.: National Academy Press, 1984.
- Article
Physician-Induced Demand for Medical Care
By: Jerry R. Green
This paper addresses the theoretical models designed to ascertain the existence of a variable level of physicians' activity in shifting the demand of their patients. Two basic approaches are followed: equilibrium models of the demand for health care, and disequilibrium...
View Details
Keywords:
Physicians;
Economic Equilibrium;
Monopolistic Competition;
Economic Competition;
Medical Care
Green, Jerry R. "Physician-Induced Demand for Medical Care." Special Issue on National Bureau of Economic Research Conference on the Economics of Physician and Patient Behavior. Journal of Human Resources 13, Suppl. (1978).
- October 1976 (Revised February 1987)
- Case
Cramer Electronics, Inc.
Designed to be the second day of a two-day series on the electronic component distribution industry, following a day spent discussing Note on the Electronic Component Distribution Industry and Raytheon Co.: Diversification. The important teaching themes which this case...
View Details
Keywords:
Change Management;
Innovation Strategy;
Management Style;
Resource Allocation;
Opportunities;
Corporate Strategy;
Diversification;
Distribution Industry;
Electronics Industry
Porter, Michael E. "Cramer Electronics, Inc." Harvard Business School Case 377-063, October 1976. (Revised February 1987.)
- Forthcoming
- Article
A Machine Learning Algorithm Predicting Risk of Dilating VUR among Infants with Hydronephrosis Using UTD Classification
By: Hsin-Hsiao Scott Wang, Michael Lingzhi Li, Dylan Cahill, John Panagides, Tanya Logvinenko, Jeanne Chow and Caleb Nelson
Backgrounds: Urinary Tract Dilation (UTD) classification has been designed to be a more objective grading system to evaluate antenatal and post-natal UTD. Due to unclear association between UTD classifications to specific anomalies such as vesico-ureteral reflux (VUR),...
View Details
Wang, Hsin-Hsiao Scott, Michael Lingzhi Li, Dylan Cahill, John Panagides, Tanya Logvinenko, Jeanne Chow, and Caleb Nelson. "A Machine Learning Algorithm Predicting Risk of Dilating VUR among Infants with Hydronephrosis Using UTD Classification." Journal of Pediatric Urology (forthcoming). (Pre-published online November 9, 2023.)
- Forthcoming
- Article
Chatbots and Mental Health: Insights into the Safety of Generative AI
By: Julian De Freitas, Ahmet Kaan Uğuralp, Zeliha Uğuralp and Stefano Puntoni
Chatbots are now able to engage in sophisticated conversations with consumers. Due to the ‘black box’ nature of the algorithms, it is impossible to predict in advance how these conversations will unfold. Behavioral research provides little insight into potential safety...
View Details
Keywords:
Autonomy;
Chatbots;
New Technology;
Brand Crises;
Mental Health;
Large Language Model;
AI and Machine Learning;
Behavior;
Well-being;
Technological Innovation;
Ethics
De Freitas, Julian, Ahmet Kaan Uğuralp, Zeliha Uğuralp, and Stefano Puntoni. "Chatbots and Mental Health: Insights into the Safety of Generative AI." Journal of Consumer Psychology (forthcoming). (Pre-published online October 26, 2023.)
- Forthcoming
- Article
Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms
By: Caroline Marra and Ariel D. Stern
Digital health technologies (DHTs) can enable more patient-centric therapeutic development by generating evidence that captures how patients feel and function, enabling decentralized trial designs that increase participant inclusivity and convenience, and collecting...
View Details
Keywords:
Health Care and Treatment;
Technological Innovation;
Product Development;
Health Testing and Trials;
Governing Rules, Regulations, and Reforms
Marra, Caroline, and Ariel D. Stern. "Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms." Clinical Pharmacology & Therapeutics (forthcoming). (Pre-published online February 2, 2024.)
- ←
- 9